Your browser doesn't support javascript.
Efficacy and tolerability of bevacizumab in patients with severe Covid-19.
Pang, Jiaojiao; Xu, Feng; Aondio, Gianmarco; Li, Yu; Fumagalli, Alberto; Lu, Ming; Valmadre, Giuseppe; Wei, Jie; Bian, Yuan; Canesi, Margherita; Damiani, Giovanni; Zhang, Yuan; Yu, Dexin; Chen, Jun; Ji, Xiang; Sui, Wenhai; Wang, Bailu; Wu, Shuo; Kovacs, Attila; Revera, Miriam; Wang, Hao; Jing, Xu; Zhang, Ying; Chen, Yuguo; Cao, Yihai.
  • Pang J; Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Xu F; Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Aondio G; Clinical Research Center of Shandong University, Jinan, Shandong, China.
  • Li Y; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Jinan, Shandong, China.
  • Fumagalli A; Department of Medicine and Oncology, Moriggia-Pelascini Hospital, Gravedona ed Uniti, Gravedona, Italy.
  • Lu M; Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Valmadre G; Department of Medicine and Oncology, Moriggia-Pelascini Hospital, Gravedona ed Uniti, Gravedona, Italy.
  • Wei J; Clinical Research Center of Shandong University, Jinan, Shandong, China.
  • Bian Y; Department of Medicine and Oncology, Moriggia-Pelascini Hospital, Gravedona ed Uniti, Gravedona, Italy.
  • Canesi M; Department of Emergency Medicine, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
  • Damiani G; Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Zhang Y; Department of Neurological Rehabilitation, Moriggia-Pelascini Hospital, Gravedona ed Uniti, Gravedona, Italy.
  • Yu D; Department of Radiology, Moriggia-Pelascini Hospital, Gravedona ed Uniti, Gravedona, Italy.
  • Chen J; Clinical Research Center of Shandong University, Jinan, Shandong, China.
  • Ji X; Department of Radiology, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Sui W; Department of Radiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
  • Wang B; Department of Pulmonary and Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Wu S; Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education, Chinese National Health Commission and Chinese Academy of Medical Sciences, The State and Shandong Province Joint Key Laboratory of Translational Cardiovascular Medicine, Jinan, Shandong, China.
  • Kovacs A; Clinical Research Center of Shandong University, Jinan, Shandong, China.
  • Revera M; Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Wang H; Department of Intensive Care Unit, Moriggia-Pelascini Hospital, Gravedona ed Uniti, Gravedona, 22015, Italy.
  • Jing X; Department of Cardiology, Moriggia-Pelascini Hospital, Gravedona ed Uniti, Gravedona, 22015, Italy.
  • Zhang Y; Department of Critical Care Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, 250012, China.
  • Chen Y; Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University, Jinan, Shandong, China.
  • Cao Y; Department of Emergency Medicine, Shandong Provincial Clinical Research Center for Emergency and Critical Care Medicine, Institute of Emergency and Critical Care Medicine of Shandong University, Qilu Hospital of Shandong University, Jinan, Shandong, China.
Nat Commun ; 12(1): 814, 2021 02 05.
Article in English | MEDLINE | ID: covidwho-1065864
Semantic information from SemMedBD (by NLM)
1. bevacizumab TREATS COVID-19
Subject
bevacizumab
Predicate
TREATS
Object
COVID-19
2. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
3. bevacizumab TREATS Patients
Subject
bevacizumab
Predicate
TREATS
Object
Patients
4. COVID-19 CAUSES Pulmonary Pathology
Subject
COVID-19
Predicate
CAUSES
Object
Pulmonary Pathology
5. Fever PROCESS_OF Patients
Subject
Fever
Predicate
PROCESS_OF
Object
Patients
6. bevacizumab TREATS COVID-19
Subject
bevacizumab
Predicate
TREATS
Object
COVID-19
7. COVID-19 PROCESS_OF Patients
Subject
COVID-19
Predicate
PROCESS_OF
Object
Patients
8. bevacizumab TREATS Patients
Subject
bevacizumab
Predicate
TREATS
Object
Patients
9. COVID-19 CAUSES Pulmonary Pathology
Subject
COVID-19
Predicate
CAUSES
Object
Pulmonary Pathology
10. Fever PROCESS_OF Patients
Subject
Fever
Predicate
PROCESS_OF
Object
Patients
ABSTRACT
On the basis of Covid-19-induced pulmonary pathological and vascular changes, we hypothesize that the anti-vascular endothelial growth factor (VEGF) drug bevacizumab might be beneficial for treating Covid-19 patients. From Feb 15 to April 5, 2020, we conducted a single-arm trial (NCT04275414) and recruited 26 patients from 2-centers (China and Italy) with severe Covid-19, with respiratory rate ≥30 times/min, oxygen saturation ≤93% with ambient air, or partial arterial oxygen pressure to fraction of inspiration O2 ratio (PaO2/FiO2) >100 mmHg and ≤300 mmHg, and diffuse pneumonia confirmed by chest imaging. Followed up for 28 days. Among these, bevacizumab plus standard care markedly improves the PaO2/FiO2 ratios at days 1 and 7. By day 28, 24 (92%) patients show improvement in oxygen-support status, 17 (65%) patients are discharged, and none show worsen oxygen-support status nor die. Significant reduction of lesion areas/ratios are shown in chest computed tomography (CT) or X-ray within 7 days. Of 14 patients with fever, body temperature normalizes within 72 h in 13 (93%) patients. Relative to comparable controls, bevacizumab shows clinical efficacy by improving oxygenation and shortening oxygen-support duration. Our findings suggest bevacizumab plus standard care is highly beneficial for patients with severe Covid-19. Randomized controlled trial is warranted.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bevacizumab / SARS-CoV-2 / COVID-19 Type of study: Controlled clinical trial / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia / Europa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-21085-8

Full text: Available Collection: International databases Database: MEDLINE Main subject: Bevacizumab / SARS-CoV-2 / COVID-19 Type of study: Controlled clinical trial / Randomized controlled trials Limits: Aged / Female / Humans / Male / Middle aged Country/Region as subject: Asia / Europa Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2021 Document Type: Article Affiliation country: S41467-021-21085-8